215 completed, 56 terminated, 29 unknown, 20 recruiting. 172 Phase 2, 132 Phase 1, 30 Phase 3, 16 Not applicable, 11 Phase 4.
Follow Non-Hodgkin's Lymphoma: new trials by email Literature Review of Non-Hodgkin's Lymphoma trials Research Report on Non-Hodgkin's Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEX101 in B-cell Non-Hodgkin's Lymphoma BEX101 injection - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-10-15 | 2026-10-22 |
| Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA KSVCBD injection - Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | Chinese PLA General Hospital | 9 | 2026-07-16 | 2026-07-20 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) Intravenous immunoglobulin, Trimethoprim / Sulfamethoxazole, Amoxicillin clavulanic acid - Myeloma, Non-Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma ABBV-291 - Non-Hodgkin's Lymphoma | Phase 1 | Active not recruiting | AbbVie | 21 | 2025-01-16 | 2026-09-29 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma After preconditioning with chemotherapy, F01 will be evaluated. - Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Shanghai Simnova Biotechnology Co.,Ltd. | 55 | 2024-04-01 | 2024-02-23 |
| A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies GNC-035 - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 40 | 2023-11-01 | 2026-08-27 |
| Living Conditions After Non-Hodgkin's Lymphoma in France Data collection, Questionnaires - Non-hodgkin's Lymphoma | Completed | Centre Hospitalier Universitaire Dijon | 1570 | 2023-09-01 | 2025-07-23 | |
| A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL MBS303 - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 132 | 2023-06-28 | 2024-11-20 |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets ABBV-525 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 78 | 2023-04-04 | 2026-05-04 |
| A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma GNC-038 - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 40 | 2022-09-26 | 2026-08-27 |
| Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy ThisCART19A - Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Zhejiang University | 16 | 2022-03-18 | 2022-04-27 |
| CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases CD70 CAR T-cells - Acute Myeloid Leukemia, Non-hodgkin's Lymphoma | Early Phase 1 | Recruiting | Zhejiang University | 108 | 2021-11-18 | 2021-11-04 |
| Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study RiTUXimab Injection [Truxima] - Non-Hodgkin's Lymphoma | Phase 4 | Unknown | Laida Cuevas Palomares | 48 | 2021-09-28 | 2022-03-31 |
| 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma [ 18F]F-AraG PET - Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Stanford University | 2 | 2021-09-28 | 2025-02-06 |
| Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma CD19+22 CAR-T cells - Non-hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 100 | 2021-05-01 | 2022-01-25 |
| A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies CAR-T cells, Ommaya Reservoir - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Early Phase 1 | Recruiting | Zhejiang University | 72 | 2020-11-01 | 2020-10-26 |
Showing 20 of 345. Sign in to see all of them.
Lymphoma, Non-Hodgkin (345) · Hodgkin Disease (78) · Lymphoma (62) · Multiple Myeloma (53) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (43) · Myelodysplastic Syndromes (39) · Leukemia, Myeloid, Acute (36) · Lymphoma, Mantle-Cell (32) · Leukemia (30) · Neoplasms (27) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (24) · Lymphoma, Follicular (20) · Lymphoma, Large B-Cell, Diffuse (19) · Recurrence (19)
Hemic and Lymphatic Diseases (345) · Immune System Diseases (345) · Immunoproliferative Disorders (345) · Lymphatic Diseases (345) · Neoplasms by Histologic Type (345) · Lymphoproliferative Disorders (341) · Neoplasms (318) · Lymphoma (283) · Hematologic Diseases (121) · Pathological Conditions, Signs and Symptoms (77) · Pathologic Processes (76) · Disease Attributes (72) · Leukemia, Lymphoid (69) · Leukemia (66) · Chronic Disease (56)
Rituximab (82) · Cyclophosphamide (30) · Bendamustine Hydrochloride (23) · Etoposide (18) · fludarabine (16) · Vincristine (15) · Doxorubicin (13) · Filgrastim (13) · Prednisone (13) · Bortezomib (12) · Granulocyte Colony-Stimulating Factor (12) · Melphalan (11) · Cytarabine (10) · fludarabine phosphate (10) · pegfilgrastim (10)
Hoffmann-La Roche (20) · Memorial Sloan Kettering Cancer Center (20) · Amgen (13) · AbbVie (11) · Dana-Farber Cancer Institute (9) · Genentech, Inc. (7) · Weill Medical College of Cornell University (7) · Gilead Sciences (6) · National Cancer Institute (NCI) (6) · Corixa Corporation (5) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (5) · Baylor College of Medicine (4) · Biogen (4) · Cephalon (4) · Eli Lilly and Company (4)
United States (233) · China (27) · France (27) · Germany (27) · Canada (26) · Australia (25) · United Kingdom (25) · Italy (24) · Spain (20) · Japan (16) · Israel (14) · South Korea (14) · Russia (12) · Belgium (11) · Poland (11)
Cheolwon Suh, MD, PhD (3) · Helen E Heslop, MD (3) · John P Leonard, MD (3) · William Wegener, MD, PhD (3) · Abhinav Deol, M.D. (2) · Andrew Spencer, Assoc. Prof (2) · Anil Tulpule, MD (2)
PMID 31050355, PMID 19451441, PMID 12907446, PMID 18165618, PMID 18268285, PMID 18839172, PMID 18997171, PMID 19018755, PMID 19547918, PMID 19706886, PMID 20107229, PMID 20118030, PMID 20235190, PMID 20594195, PMID 20626754, PMID 21196441, PMID 21239695, PMID 21724462, PMID 22047558, PMID 22198152, PMID 22438256, PMID 23088650, PMID 23276888, PMID 23834234, PMID 23843495, PMID 23913470, PMID 23960180, PMID 23990665, PMID 24002601, PMID 24048792, PMID 24085766, PMID 24265828, PMID 24521993, PMID 24591201, PMID 24717109, PMID 24720836, PMID 24753538, PMID 24761968, PMID 24824768, PMID 24827808, PMID 24911148, PMID 25204639, PMID 25404094, PMID 25482239, PMID 25568347, PMID 25665464, PMID 25909710, PMID 26072403, PMID 26282650, PMID 26639404
2016 (3), 2009 (2), 2015 (2), 2017 (2), 2018 (2), 2004 (1), 2008 (1), 2014 (1), 2019 (1), 2023 (1), 4UL1TR000427-10 (1), P30CA014520 (1), P50CA126752 (1)